Regulatory Fate of Cancer Indications in the European Union After Accelerated Approval in the US

IF 22.5 1区医学 Q1 ONCOLOGY

JAMA Oncology Pub Date : 2024-11-14 DOI:10.1001/jamaoncol.2024.5145

Tonny Studsgaard Petersen, Kristian Karstoft, Freja Karuna Hemmingsen Sørup, Marie Lund, Allan Cramer

引用次数: 0

Abstract

This cohort study investigates the regulatory fate in the European Union for drugs that received accelerated approval for cancer indications in the US.

查看原文本刊更多论文

癌症适应症在美国加速批准后在欧盟的监管命运

这项队列研究调查了在美国获得癌症适应症加速审批的药物在欧盟的监管命运。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JAMA Oncology Medicine-Oncology

自引率

1.80%

发文量

423

期刊介绍： JAMA Oncology is an international peer-reviewed journal that serves as the leading publication for scientists, clinicians, and trainees working in the field of oncology. It is part of the JAMA Network, a collection of peer-reviewed medical and specialty publications.